Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect

Report final results of a phase I/II study of VB-111, a targeted anti-cancer gene therapy with a dual mechanism: anti angiogenic/vascular disruption and induction of an anti-tumor directed immune response, in combination with paclitaxel in patients with platinum-resistant ovarian cancer. Study NCT01...

Full description

Saved in:

Bibliographic Details
Published in:	Gynecologic oncology Vol. 157; no. 3; pp. 578 - 584
Main Authors:	Arend, Rebecca C., Beer, Hannah M., Cohen, Yael C., Berlin, Suzanne, Birrer, Michael J., Campos, Susana M., Rachmilewitz Minei, Tamar, Harats, Dror, Wall, Jaclyn A., Foxall, McKenzie E., Penson, Richard T.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.06.2020
Subjects:	Aged Anti-angiogenic Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bleomycin - pharmacology Bleomycin - therapeutic use Cisplatin - pharmacology Cisplatin - therapeutic use Female Gene therapy Hematology, Oncology, and Palliative Medicine Humans Immunotherapeutic Immunotherapy - methods Middle Aged Obstetrics and Gynecology Ovarian Neoplasms - drug therapy Platinum-resistant Platinum-resistant ovarian cancer VB-111 Vinblastine - pharmacology Vinblastine - therapeutic use VB-111 Gene therapy Anti-angiogenic Platinum-resistant ovarian cancer Immunotherapeutic Platinum-resistant
ISSN:	0090-8258, 1095-6859, 1095-6859
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!